Vascular Care Group Enrolls First Patient in FORTAVENA Study

The Vascular Care Group (TVCG) has enrolled the first patient in the United States for the FORTAVENA Post-Market Study. The study, officially titled "The GORE® VIABAHN® FORTEGRA Venous Stent Post-Approval Study," focuses on the performance of the GORE® VIABAHN® FORTEGRA Venous Stent.

This post-market research aims to gather additional data on the stent's effectiveness and safety after it has received regulatory approval. The enrollment took place at TVCG's vascular center in Darien, Connecticut.

The study's objective is to confirm the long-term efficacy and patient safety of the stent material in real-world clinical settings. Findings from the study could inform future treatment protocols and clinical decision-making for vascular conditions.

TVCG specializes in the diagnosis and treatment of vascular diseases. The organization has previously participated in clinical trials to advance the field of vascular care.